Clopidogrel ( DrugBank: Clopidogrel )

3 diseases

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs071180052	26/12/2014	15/03/2019	Control of steroid-associated osteonecrosis of the femoral head in SLE patients	Clinical trial for the control of osteonecrosis of the femoral head secondary to the initial corticosteroid treatment in patients with systemic lupus erythematosus - None	systemic lupus erythematosus;D008180	Objectives take three below candidate drugs for the prevention for at least 3 months after the initial corticosteroid treatment. 1. Clopidogrel Bisulfate (Plavix) Taking a dose of 300mg once daily on the first day, and a dose of 75mg once daily on subsequent days. 2. Pitavastatin Calcium (LIVALO) Taking a dose of 2mg once daily. 3. Tocopherol Acetate (Juvela) Taking a dose of 100mg three times daily (total of 300mg daily).	Nakashima Yasuharu	NULL	Recruiting	>= 20age old	Not applicable	Both	150	Phase 2	Japan

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05098704 (ClinicalTrials.gov)	June 22, 2022	4/10/2021	Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk	Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon	Scleroderma;Systemic Sclerosis	Drug: clopidogrel treatment;Drug: Placebo	University Hospital, Bordeaux	Ministry for Health and Solidarity, France	Recruiting	18 Years	85 Years	All	90	Phase 2/Phase 3	France

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00105209 (ClinicalTrials.gov)	April 2002	9/3/2005	A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension	A Double-Blind, Placebo-Controlled, Three Treatment Cross-Over Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension	Hypertension, Pulmonary	Drug: Aspirin;Drug: clopidogrel	Kawut, Steven, MD	National Heart, Lung, and Blood Institute (NHLBI);Columbia University	Completed	18 Years	N/A	Both	20	Phase 2	United States